Novavax has announced the appointments of two new vice presidents: Dr Louis Fries III becomes vice president, clinical and medical affairs; and Dr Jane Halpern, becomes vice president of regulatory affairs.
Before joining Novavax, Dr Fries was director, global clinical development at GSK Biologicals, North America and Dr Halpern was staff scientist and regulatory affairs specialist at the Vaccine Research Center of the National Institute of Allergy and Infectious Disease (NIAID), National Institutes of Health.
‘We are excited to welcome these two highly talented senior executives to our company,’ said Dr Gregory Glenn, Novavax's senior vice president and chief medical officer. ‘Each brings extensive experience in the development, clinical testing and registration of influenza and novel vaccines and more than two decades of industry and government experience.’
Stanley Erck, president and ceo of Novavax, added: ‘These appointments reflect our commitment to strengthening the Novavax management team as we work to advance and commercialise our VLP technology worldwide.’
